Abstract 490P
Background
EGFR T790M mutations have been reported to occur in about 50% of patients (pts) at progression on 1st/2nd generation EGFR TKI therapy. These pts benefit from treatment with 3rd generation EGFR TKI osimertinib. However, observational real-world studies show that the proportion of pts receiving 2nd line osimertinib is lower than expected. We aimed to evaluate these treatment patterns and outcomes in our institution.
Methods
In this prospective observational study, survival, response and treatment data was collected from pts with EGFR mutant advanced NSCLC who received EGFR TKIs in the 1st line, who were treated in our institution from September 2012 to December 2017. Institutional approval was obtained and all patients provided written, informed consent.
Results
108 pts (median age 65 years, 54% females, 75% never smokers, 54% EGFR exon 19 deletion) were enrolled of whom 48 (44%) received gefitinib, 38 (35%) erlotinib and 22 (20%) afatinib in the 1st line. The median overall survival (OS) was 33.1 months (95% CI 24.5-41.7) and median progression free survival (PFS) was 11.1 months (95% CI 8.5-13.7). 83 pts (77%) had progressed at the time of analysis, and 48/83 patients (58%) underwent T790M testing. Of these, 25/48 (52%) were T790M positive. 21/83 pts went on to receive osimertinib in the 2nd line (25% of all patients who progressed on 1st line therapy)- OS was not reached in these pts. 12/83 pts received 2nd line chemotherapy (15%); 32/83 pts (39%) did not receive any 2nd line treatment. OS was 42.3 months (95% CI 24.2-50.4) and 18.2 months (95% CI 11.6-24.7) in these groups respectively.
Conclusions
In this prospective real-world study, a significant proportion of patients did not receive 2nd line therapy after progression on 1st/2nd generation TKIs. The rates of T790M mutations when tested was comparable to that reported in the literature. Some reasons for not receiving 2nd line therapy included low testing rates for EGFR T790M and patient fitness for 2nd line therapy. This suboptimal use of osimertinib in the 2nd line setting, together with favourable PFS data for osimertinib in the 1st line, favours the upfront use of osimertinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C.S. Tan: Honoraria (self): AstraZeneca; Honoraria (self): Merck; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Novartis; Honoraria (self): Eli-Lilly; Honoraria (self): Eisai; Honoraria (self): BMS. R.A. Soo: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self): BMS; Honoraria (self), Research grant / Funding (self): Boehringer Ingelheim; Honoraria (self): Celgene; Honoraria (self): Ignyta; Honoraria (self): Lilly; Honoraria (self): Merck; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self): Taiho; Honoraria (self): Takeda; Honoraria (self): Yuhan. All other authors have declared no conflicts of interest.
Resources from the same session
284P - Differences in disease characteristics and survival outcomes of follicular lymphoma in young adults and older population: An institutional analysis
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract
285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Presenter: Christine Mauz-koerholz
Session: Poster display session
Resources:
Abstract
294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
Presenter: Li-rong Wu
Session: Poster display session
Resources:
Abstract
295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
Presenter: Sik Kwan Chan
Session: Poster display session
Resources:
Abstract
296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution
Presenter: Wan Ping Ch' ng
Session: Poster display session
Resources:
Abstract
297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study
Presenter: Myung-Ju Ahn
Session: Poster display session
Resources:
Abstract
298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
Presenter: Sang-Hee Cho
Session: Poster display session
Resources:
Abstract
299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer
Presenter: Sudibio Sudibio
Session: Poster display session
Resources:
Abstract
300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma
Presenter: Ming-Yuan Chen
Session: Poster display session
Resources:
Abstract
301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension
Presenter: Karan Gupta
Session: Poster display session
Resources:
Abstract